These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19625189)

  • 1. Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists.
    Didiuk MT; Griffith DA; Benbow JW; Liu KK; Walker DP; Bi FC; Morris J; Guzman-Perez A; Gao H; Bechle BM; Kelley RM; Yang X; Dirico K; Ahmed S; Hungerford W; DiBrinno J; Zawistoski MP; Bagley SW; Li J; Zeng Y; Santucci S; Oliver R; Corbett M; Olson T; Chen C; Li M; Paralkar VM; Riccardi KA; Healy DR; Kalgutkar AS; Maurer TS; Nguyen HT; Frederick KS
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4555-9. PubMed ID: 19625189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis.
    Kalgutkar AS; Griffith DA; Ryder T; Sun H; Miao Z; Bauman JN; Didiuk MT; Frederick KS; Zhao SX; Prakash C; Soglia JR; Bagley SW; Bechle BM; Kelley RM; Dirico K; Zawistoski M; Li J; Oliver R; Guzman-Perez A; Liu KK; Walker DP; Benbow JW; Morris J
    Chem Res Toxicol; 2010 Jun; 23(6):1115-26. PubMed ID: 20507089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New aminopropandiol derivatives as orally available and short-acting calcium-sensing receptor antagonists.
    Shinagawa Y; Inoue T; Hirata K; Katsushima T; Nakagawa T; Matsuo Y; Shindo M; Hashimoto H
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3809-13. PubMed ID: 20472433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel and potent calcium-sensing receptor antagonists: discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent.
    Yoshida M; Mori A; Morimoto S; Kotani E; Oka M; Notoya K; Makino H; Ono M; Shirasaki M; Tada N; Fujita H; Ban J; Ikeda Y; Kawamoto T; Goto M; Kimura H; Baba A; Yasuma T
    Bioorg Med Chem; 2011 Mar; 19(6):1881-94. PubMed ID: 21353570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation.
    Kumar S; Matheny CJ; Hoffman SJ; Marquis RW; Schultz M; Liang X; Vasko JA; Stroup GB; Vaden VR; Haley H; Fox J; DelMar EG; Nemeth EF; Lago AM; Callahan JF; Bhatnagar P; Huffman WF; Gowen M; Yi B; Danoff TM; Fitzpatrick LA
    Bone; 2010 Feb; 46(2):534-42. PubMed ID: 19786130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists.
    Widler L; Altmann E; Beerli R; Breitenstein W; Bouhelal R; Buhl T; Gamse R; Gerspacher M; Halleux C; John MR; Lehmann H; Kalb O; Kneissel M; Missbach M; Müller IR; Reidemeister S; Renaud J; Taillardat A; Tommasi R; Weiler S; Wolf RM; Seuwen K
    J Med Chem; 2010 Mar; 53(5):2250-63. PubMed ID: 20158186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core.
    Harrington PE; St Jean DJ; Clarine J; Coulter TS; Croghan M; Davenport A; Davis J; Ghiron C; Hutchinson J; Kelly MG; Lott F; Lu JY; Martin D; Morony S; Poon SF; Portero-Larragueta E; Reagan JD; Regal KA; Tasker A; Wang M; Yang Y; Yao G; Zeng Q; Henley C; Fotsch C
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5544-7. PubMed ID: 20708930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel and potent orally active calcium-sensing receptor antagonists that stimulate pulselike parathyroid hormone secretion: synthesis and structure-activity relationships of tetrahydropyrazolopyrimidine derivatives.
    Yoshida M; Mori A; Kotani E; Oka M; Makino H; Fujita H; Ban J; Ikeda Y; Kawamoto T; Goto M; Kimura H; Baba A; Yasuma T
    J Med Chem; 2011 Mar; 54(5):1430-40. PubMed ID: 21306167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis.
    Shcherbakova I; Balandrin MF; Fox J; Ghatak A; Heaton WL; Conklin RL
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1557-60. PubMed ID: 15745796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.
    Marquis RW; Lago AM; Callahan JF; Trout RE; Gowen M; DelMar EG; Van Wagenen BC; Logan S; Shimizu S; Fox J; Nemeth EF; Yang Z; Roethke T; Smith BR; Ward KW; Lee J; Keenan RM; Bhatnagar P
    J Med Chem; 2009 Jul; 52(13):3982-93. PubMed ID: 19492813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones.
    Shcherbakova I; Huang G; Geoffroy OJ; Nair SK; Swierczek K; Balandrin MF; Fox J; Heaton WL; Conklin RL
    Bioorg Med Chem Lett; 2005 May; 15(10):2537-40. PubMed ID: 15863312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationships of 3H-quinazolin-4-ones and 3H-pyrido[2,3-d]pyrimidin-4-ones as CXCR3 receptor antagonists.
    Storelli S; Verzijl D; Al-Badie J; Elders N; Bosch L; Timmerman H; Smit MJ; De Esch IJ; Leurs R
    Arch Pharm (Weinheim); 2007 Jun; 340(6):281-91. PubMed ID: 17562560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
    J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis.
    Widler L
    Future Med Chem; 2011 Apr; 3(5):535-47. PubMed ID: 21526895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel dihydrobenzofuran cyclopropane carboxylic acid based calcium sensing receptor antagonists for the treatment of osteoporosis.
    Liang GB; Zhou C; Huo X; Wang H; Yang X; Huang S; Wang H; Wilkinson H; Luo L; Tang W; Sutton D; Li H; Zaller D; Meinke PT
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4077-80. PubMed ID: 27397499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and structure-activity relationships of trisubstituted pyrimidines/pyridines as novel calcium-sensing receptor antagonists.
    Yang W; Ruan Z; Wang Y; Van Kirk K; Ma Z; Arey BJ; Cooper CB; Seethala R; Feyen JH; Dickson JK
    J Med Chem; 2009 Feb; 52(4):1204-8. PubMed ID: 19143533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationship of tetrahydropyrazolopyrimidine derivatives--a novel structural class of potent calcium-sensing receptor antagonists.
    Yoshida M; Mori A; Inaba A; Oka M; Makino H; Yamaguchi M; Fujita H; Kawamoto T; Goto M; Kimura H; Baba A; Yasuma T
    Bioorg Med Chem; 2010 Dec; 18(24):8501-11. PubMed ID: 21055954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of substituted 3H-pyrido[2,3-d]pyrimidin-4-ones as potent, biased, and orally bioavailable sst2 agonist.
    Zhao J; Chen Z; Kusnetzow AK; Nguyen J; Rico-Bautista E; Tan H; Betz SF; Struthers RS; Zhu Y
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127496. PubMed ID: 32805408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo.
    Arey BJ; Seethala R; Ma Z; Fura A; Morin J; Swartz J; Vyas V; Yang W; Dickson JK; Feyen JH
    Endocrinology; 2005 Apr; 146(4):2015-22. PubMed ID: 15637285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Li JJ; Nahra J; Johnson AR; Bunker A; O'Brien P; Yue WS; Ortwine DF; Man CF; Baragi V; Kilgore K; Dyer RD; Han HK
    J Med Chem; 2008 Feb; 51(4):835-41. PubMed ID: 18251495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.